■六氢大麻酚是大麻酚的六氢衍生物。2022年5月在欧洲首次观察到六氢大麻酚中毒。
■这是一项回顾性观察性研究,对2022年1月1日至2023年5月31日期间法国毒物中心报告的自我报告六氢大麻酚暴露病例进行了观察。
■有37例,包括2023年5月的19。患者的中位年龄为36岁(四分位距28-43),大多数是男人。8例患者有物质使用障碍史。暴露途径是在24中摄入,在10中吸入(吸烟或vaping),在2中吸入和摄入,在1中舌下。临床特征为神经系统(85%),心血管(61%),胃肠(33%),精神病(27%)和眼科(21%)。59%的患者住院。在四名患者中,中毒严重程度评分为0(无症状);在15例患者中,得分为1(次要);在16中,得分为2(中等);在两种情况下,评分为3分(严重)。在70%的患者中,结果是已知的,一切都恢复了。仅在6个病例中进行了生物样本测试。五名患者的六氢大麻酚的血液或尿液检查呈阳性;在两名患者中,还检测到四氢大麻酚和代谢物。此外,还有另外一名患者在使用的物质中检测到Δ8-和Δ9-四氢大麻酚。
■本系列报告的临床效应包括神经精神和躯体效应。虽然这些病例与自我报告使用六氢大麻酚有关,在相当大比例的病例中,四氢大麻酚的使用也可能导致这种效应.本研究有一定的局限性,例如,由于研究的回顾性性质,缺乏可用的信息。因此,它可能高估了中度和重度病例的数量,因为少报了轻微或没有严重的病例。仅对6名患者进行了血液和尿液分析,所以我们不能确定其他病人消费的产品是六氢大麻酚。
■六氢大麻酚的临床作用是神经系统的,心血管,胃肠,主要是精神病和眼部,有时很严重。
UNASSIGNED: Hexahydrocannabinol is a hexahydro derivative of cannabinol. Poisoning with hexahydrocannabinol was first observed in Europe in May 2022.
UNASSIGNED: This is a retrospective observational study of cases of self-reported hexahydrocannabinol exposure reported to French poison centres between 1 January 2022 and 31 May 2023.
UNASSIGNED: There were 37 cases, including 19 in May 2023. The median age of the patients was 36 (interquartile range 28-43) years, and most were men. Eight patients had a history of substance use disorder. The route of exposure was ingestion in 24, inhalation (smoking or vaping) in 10, inhalation and ingestion in two and sublingual in one. Clinical features were neurological (85 per cent), cardiovascular (61 per cent), gastrointestinal (33 per cent), psychiatric (27 per cent) and ocular (21 per cent). Fifty-nine per cent of the patients were hospitalized. In four patients, the Poisoning Severity Score was 0 (asymptomatic); in 15 patients, the Score was 1 (minor); in 16, the Score was 2 (moderate); and in two cases, the Score was 3 (severe). In 70 per cent of patients, the outcome was known, and all recovered. Testing of biological samples was only undertaken in six cases. Five patients had positive blood or urine tests for hexahydrocannabinol; in two patients, tetrahydrocannabinol and metabolites were also detected. In addition, there was an additional patient in whom Δ8- and Δ9-tetrahydrocannabinol was detected in the substances used.
UNASSIGNED: Clinical effects reported in this series included neuropsychiatric and somatic effects. Whilst these cases related to self-reported hexahydrocannabinol use, it is likely that tetrahydrocannabinol use also contributed to the effects in a substantial proportion of cases. This study has some limitations, such as the lack of available information due to the retrospective nature of the study. As a result, it probably overestimates the number of moderate and severe cases due to under-reporting of cases of little or no severity. Analysis of the patient\'s blood and urine was performed only in six patients, so we cannot be certain that the products consumed by the other patients were hexahydrocannabinol.
UNASSIGNED: The clinical effects attributed to hexahydrocannabinol were neurological, cardiovascular, gastrointestinal, psychiatric and ocular predominantly and were sometimes serious.